# CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 21-277

**CHEMISTRY REVIEW(S)** 





Chemistry Review Data Sheet

## **Chemistry Review Data Sheet**

- 1. NDA 21-277
- 2. REVIEW #: 1
- 3. REVIEW DATE: 11/26/01
- 4. REVIEWER: Dorota Matecka
- 5. PREVIOUS DOCUMENTS:

Previous Documents	Document Date
Original	11/2/00
Amendment (BC)	5/8/01
Amendment (BC)	6/13/01
Amendment (AC)	7/3/01
Amendment (BC)	8/30/01
IR letter	11/19/01
Amendment (BC)	11/20/01

### 6. SUBMISSION(S) BEING REVIEWED:

Submission(s) Reviewed	Document Date	
Original	11/2/00	
Amendment (BC)	5/8/01	
Amendment (BC)	6/13/01	
Amendment (AC)	7/3/01	
Amendment (BC)	8/30/01	
Amendment (BC)	11/20/01	

#### **CHEMISTRY REVIEW**



Chemistry Review Data Sheet

#### 7. NAME & ADDRESS OF APPLICANT:

Name:	Bayer Corporation Pharmaceutical Division
Address:	400 Morgan Lane, West Haven, CT 06516
Representative:	Andrew Verderame, Associate Director, Regulatory Affairs
Telephone:	(203) 812-5172

#### 8. DRUG PRODUCT NAME/CODE/TYPE:

- a) Proprietary Name: AVELOX I.V.
- b) Non-Proprietary Name (USAN): moxifloxacin hydrochloride in sodium chloride injection
- c) Code Name/#: BAY 12-8039 (moxifloxacin hydrochloride)
- d) Chem. Type/Submission Priority (ONDC only):
  - Chem. Type: 3
  - Submission Priority: S
- 9. LEGAL BASIS FOR SUBMISSION: N/A
- 10. PHARMACOL. CATEGORY: Antibacterial
- 11. DOSAGE FORM: intravenous solution
- 12. STRENGTH/POTENCY: 0.16% (400 mg)
- 13. ROUTE OF ADMINISTRATION: intravenous
- 14. Rx/OTC DISPENSED: X Rx OTC
- 15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
  \_\_\_\_\_SPOTS product Form Completed

X Not a SPOTS product



Chemistry Review Data Sheet

# 16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

Moxifloxacin Hydrochloride,  $C_{21}H_{24}N_3FO_4$  x HCl, MW = 437.9 Monohydrochloride salt of 1-cyclopropyl-7-[(S,S)-2,8-diazabicyclo[4.3.0]non-8-yl]-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinoline carboxylic acid

#### 17. RELATED/SUPPORTING DOCUMENTS:

#### A. DMFs:

DMF# TYPE HOLDER	ITEM REFERENCED	COD E <sup>1</sup>	STATUS <sup>2</sup>	DATE REVIEW COMPLETED	COMMENTS
------------------	--------------------	-----------------------	---------------------	-----------------------------	----------

1 - DMF Reviewed.

Other codes indicate why the DMF was not reviewed, as follows:

- 2-Type 1 DMF
- 3 Reviewed previously and no revision since last review
- 4 Sufficient information in application
- 5 Authority to reference not granted
- 6 DMF not available
- 7 Other (explain under "Comments")

<sup>&</sup>lt;sup>1</sup> Action codes for DMF Table:

<sup>&</sup>lt;sup>2</sup> Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)



### **CHEMISTRY REVIEW**



#### Chemistry Review Data Sheet

#### B. Other Documents:

DOCUMENT	APPLICATION NUMBER	DESCRIPTION
NDA	21-085	AVELOX Tablets

### **18. STATUS:**

CONSULTS/ CMC RELATED REVIEWS	RECOMMENDATION	DATE	REVIEWER
EES	Acceptable	10/22/01	N/A
OPDRA	Acceptable	4/26/01	Carol Holquist, R.Ph.
EA	Categorical exclusion	N/A	N/A
Microbiology	Acceptable	10/17/01	Vinnie Pawar, Ph.D.

# APPEARS THIS WAY ON ORIGINAL

APPEARS THIS WAY ON ORIGINAL